| Mar 26 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 152.73K | $ 135.06K | $ 82.41K | $ 75.58K | $ 32.44K |
| Gross Profit | $ 0.00 | $ 135.06K | $ 40.17K | $ -73.67K | $ 22.63K |
| Operating Income | $ -1.16M | $ -1.60M | $ -2.10M | $ -1.87M | $ -2.94M |
| EBITDA | $ -1.16M | $ -1.62M | $ -2.10M | $ -4.80M | $ -3.98M |
| Net Income | $ -895.97K | $ -1.63M | $ -2.11M | $ -6.34M | $ -4.33M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.86K | $ 126.04K | $ 136.46K | $ 426.98K | $ 18.71K |
| Total Assets | $ 494.08K | $ 300.36K | $ 304.85K | $ 653.97K | $ 311.84K |
| Total Debt | $ 537.50K | $ 20.93K | $ 100.00K | $ 43.84K | $ 388.80K |
| Net Debt | $ 533.64K | $ -105.10K | $ -36.46K | $ -383.14K | $ 370.08K |
| Total Liabilities | $ 2.79M | $ 943.17K | $ 681.70K | $ 164.84K | $ 501.72K |
| Stockholders' Equity | $ -2.29M | $ -642.81K | $ -376.86K | $ 489.13K | $ -189.88K |
| Cash Flow | |||||
| Free Cash Flow | $ -636.70K | $ -1.25M | $ -1.19M | $ -786.03K | $ -662.59K |
| Operating Cash Flow | $ -636.70K | $ -1.25M | $ -1.19M | $ -786.03K | $ -662.59K |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 40.00K | $ -40.00K | $ -125.00K |
| Financing Cash Flow | $ 590.55K | $ 1.24M | $ 856.48K | $ 1.23M | $ 791.35K |
CB Scientific Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.